H Bartelink

发表

Human tumour cell kinetics using a monoclonal antibody against iododeoxyuridine: intratumour sampling variations.

H. Bartelink, A. Begg, L. Moonen, 1988, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Fractionation in radiotherapy.

H. Bartelink, L. Moonen, L Moonen, 1994, Cancer treatment reviews.

Target volumes in radiotherapy for high-grade malignant glioma of the brain.

M van Herk, H. Bartelink, M. V. van Herk, 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

A reversal of fortune: practical problems in the monitoring and interpretation of an EORTC breast cancer trial.

R Sylvester, H. Bartelink, R. Sylvester, 1994, Statistics in medicine.

Quality of life of early-stage breast cancer patients treated with radical mastectomy or breast-conserving procedures: results of EORTC Trial 10801. The European Organization for Research and Treatment of Cancer (EORTC), Breast Cancer Co-operative Group (BCCG).

N K Aaronson, H. Bartelink, I. Fentiman, 1998, European journal of cancer.

The potential impact of CT-MRI matching on tumor volume delineation in advanced head and neck cancer.

M van Herk, H. Bartelink, M. V. van Herk, 1997, International journal of radiation oncology, biology, physics.

Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer, EORTC 10801 trial.

E van der Schueren, R Sylvester, H. Bartelink, 1992, Journal of the National Cancer Institute. Monographs.

The volume effect in radiation-related late small bowel complications: results of a clinical study of the EORTC Radiotherapy Cooperative Group in patients treated for rectal carcinoma.

J C Horiot, J W Leer, H. Bartelink, 1994, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients?

L Collette, A Fourquet, W Van den Bogaert, 2003, European journal of cancer.

Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial.

E van der Schueren, H. Bartelink, I. Fentiman, 2001, Journal of the National Cancer Institute.

Prognostic factors of neck node metastasis.

A. Hart, H. Bartelink, G. Snow, 1982, Clinical otolaryngology and allied sciences.

First clinical experience with a newly developed electronic portal imaging device.

M van Herk, J Bijhold, H Meertens, 1990, International journal of radiation oncology, biology, physics.

Profile of radiotherapy departments contributing to the Cooperative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer.

J C Horiot, H. Bartelink, J. Horiot, 1996, International journal of radiation oncology, biology, physics.

Transfer errors of planning CT to simulator: a possible source of setup inaccuracies?

R E Vijlbrief, A Bel, H. Bartelink, 1994, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines.

H. Bartelink, J. Beijnen, A. Begg, 1998, European journal of cancer.

Potential of radiation-induced chromosome aberrations to predict radiosensitivity in human tumour cells.

H. Bartelink, W. Burrill, A. Begg, 1999, International journal of radiation biology.

A verification procedure to improve patient set-up accuracy using portal images.

M van Herk, A Bel, H. Bartelink, 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Psychological effects of breast conserving therapy in comparison with radical mastectomy.

H. Bartelink, F. V. van Dam, H Bartelink, 1985, International journal of radiation oncology, biology, physics.

The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC 'boost vs. no boost' trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups.

L Collette, A Fourquet, E Van Limbergen, 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Validation of the methods of cosmetic assessment after breast-conserving therapy in the EORTC "boost versus no boost" trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. European Organization for Research and Treatment of Cancer.

J C Horiot, L Collette, E Van Limbergen, 1999, International journal of radiation oncology, biology, physics.

Time trend of patient setup deviations during pelvic irradiation using electronic portal imaging.

A Bel, R Vijlbrief, H. Bartelink, 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

DNA‐adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy

H. Bartelink, D. de Jong, A. Begg, 2000, International journal of cancer.

Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials.

J. Peterse, H. Bartelink, R. Sylvester, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Telemedicine and its impact on cancer management.

J Ricke, H. Bartelink, J. Ricke, 2000, European journal of cancer.

Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy: long-term results of European Organisation for Research and Treatment of Cancer studies.

H Putter, H. Putter, H. Bartelink, 2006, European journal of cancer.